查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585817

液態切片市場：按生物標記、最終用戶分類 - 2025-2030 年全球預測

Breast Cancer Liquid Biopsy Market by Biomarker (Cell-free DNA, Circulating Tumor Cells, Extracellular Vesicles), End-User (Hospitals & Physician Laboratories, Reference Laboratories) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年液態切片市場價值為4.9429億美元，預計到2024年將達到5.8992億美元，複合年成長率為19.44%，到2030年將達到17.1415億美元。

乳癌液態切片市場是一個快速發展的行業，專注於微創測試，能夠實現癌症的早期檢測、監測和個人化治療。該技術透過分析患者血液中的循環腫瘤 DNA (ctDNA)，提供對腫瘤動態的全面了解。推動液態切片需求的主要因素包括全球乳癌盛行率的增加以及傳統切片檢查的局限性，例如侵入性和潛在的併發症。液態切片的應用範圍從早期檢測到監測治療效果和識別潛在的復發。最終使用領域主要包括醫院、診斷實驗室和研究機構。

主要市場統計
基準年[2023] 4.9429 億美元
預測年份 [2024] 5.8992 億美元
預測年份 [2030] 1,714.15 百萬美元
複合年成長率（%） 19.44%

市場成長受到基因組學和精準醫學技術進步、人們對早期癌症檢測益處的認知不斷提高以及向非侵入性診斷技術的轉變的影響。潛在的成長機會存在於新興市場，這些市場不斷成長的醫療保健支出和不斷提高的意識正在放大成長前景。此外，生物技術公司和研究機構之間的合作有可能加速創新並改善獲得這些先進診斷的機會。然而，挑戰仍然存在，包括高成本、監管障礙以及與傳統切片檢查相比靈敏度有限，這可能會限制市場擴張。

最佳創新領域包括提高液體生物標記檢測技術的靈敏度和特異性，以及整合人工智慧以增強液態切片資料的預測分析和解釋。專注於多種癌症的早期檢測和尋找新型生物標記的研究可以提供競爭優勢。市場高度動態且分散，來自老牌公司和新興企業的競爭非常激烈，因此公司投資研發和策略聯盟非常重要。公司應專注於最佳化成本結構和簡化監管途徑，以提高採用率。在一個以快速技術創新和複雜法規為特徵的市場中，策略規劃的敏捷性和遠見對於保持競爭優勢和推動成長至關重要。

市場動態：快速發展的液態切片市場的關鍵市場洞察

供需的動態交互作用正在改變液態切片市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球乳癌發生率上升
    • 對非侵入性乳癌治療的需求不斷增加
    • 液態切片研究和開發的潛在資金
  • 市場限制因素
    • 液態切片高成本
  • 市場機會
    • 液態切片早期檢測技術進展
    • 液態切片試劑核准增加
  • 市場挑戰
    • 嚴格的監管問題和報銷政策不足

波特五力：開拓液態切片市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解液態切片市場的外部影響

外部宏觀環境因素在塑造液態切片市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解液態切片市場的競爭格局

液態切片市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣乳癌液態切片市場供應商的績效評估

FPNV 定位矩陣是評估液態切片市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了液態切片市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對乳癌液態切片市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球乳癌發生率正在上升
      • 對非侵入性乳癌治療的需求增加
      • 液態生物檢體研究和開發的資金可用性
    • 抑制因素
      • 液態切片的費用很高。
    • 機會
      • 液態切片早期檢測技術進展
      • 液態切片試劑核准增加
    • 任務
      • 嚴重的監管問題和糟糕的報銷政策
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章液態切片市場生物標記

  • 遊離DNA
  • 循環性腫瘤細胞
  • 細胞外囊泡

第7章液態切片市場：依最終用戶分類

  • 醫院和醫生檢查室
  • 參考實驗室

第8章美洲液態切片市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太液態切片市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲液態切片市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adaptive Biotechnologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • NeoGenomics Laboratories, Inc.
  • Qiagen NV by Thermo Fisher Scientific Inc.
  • Sysmex Corporation
  • The Menarini Group
Product Code: MRR-437D45958552

The Breast Cancer Liquid Biopsy Market was valued at USD 494.29 million in 2023, expected to reach USD 589.92 million in 2024, and is projected to grow at a CAGR of 19.44%, to USD 1,714.15 million by 2030.

The breast cancer liquid biopsy market is a rapidly evolving sector focused on minimally invasive tests enabling early cancer detection, monitoring, and personalized treatment. This method involves analyzing circulating tumor DNA (ctDNA) in a patient's blood, offering a comprehensive view of tumor dynamics. Key factors driving its necessity include the increasing global prevalence of breast cancer and the limitations of traditional biopsies, such as invasiveness and potential complications. Applications of liquid biopsy span from early detection to monitoring treatment efficacy and identifying potential relapse, thus enhancing precision and personalization in patient care. End-use segments primarily include hospitals, diagnostic laboratories, and research institutes.

KEY MARKET STATISTICS
Base Year [2023] USD 494.29 million
Estimated Year [2024] USD 589.92 million
Forecast Year [2030] USD 1,714.15 million
CAGR (%) 19.44%

Market growth is influenced by technological advancements in genomics and precision medicine, increasing awareness of early cancer detection benefits, and a shift towards non-invasive diagnostic techniques. Potential opportunities lie in emerging markets, where increasing healthcare expenditure and heightened awareness amplify growth prospects. Additionally, partnerships between biotech firms and research institutions could accelerate innovation and improve accessibility to these advanced diagnostics. However, challenges remain in the form of high costs, regulatory hurdles, and limited sensitivity compared to traditional tissue biopsies, potentially restraining market expansion.

The best areas for innovation include improving the sensitivity and specificity of liquid biomarker detection techniques and integrating artificial intelligence to enhance predictive analytics and interpretation of liquid biopsy data. Research focused on multi-cancer early detection and the exploration of new biomarkers could provide competitive advantages. The market is highly dynamic and fragmented with strong competition among established players and rising startups, making it crucial for companies to invest in R&D and strategic collaborations. Businesses should focus on optimizing cost structures and simplifying regulatory pathways to enhance adoption rates. In a market characterized by rapid technological updates and regulatory complexities, agility and foresight in strategic planning are vital for sustaining competitive advantage and fostering growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Market

The Breast Cancer Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of breast cancer worldwide
    • Increasing demand for non-invasive breast cancer treatment
    • Availability of funding for liquid biopsy R&D
  • Market Restraints
    • High cost of breast cancer liquid biopsy
  • Market Opportunities
    • Technological advancements in early-stage detection of breast cancer liquid biopsy
    • Increasing breast cancer liquid biopsy reagent approvals
  • Market Challenges
    • Stringent regulatory issues and poor reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Market

A strategic analysis of the Breast Cancer Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Services, Inc., NeoGenomics Laboratories, Inc., Qiagen N. V. by Thermo Fisher Scientific Inc., Sysmex Corporation, and The Menarini Group.

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Biomarker, market is studied across Cell-free DNA, Circulating Tumor Cells, and Extracellular Vesicles.
  • Based on End-User, market is studied across Hospitals & Physician Laboratories and Reference Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer worldwide
      • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
      • 5.1.1.3. Availability of funding for liquid biopsy R&D
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of breast cancer liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
      • 5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory issues and poor reimbursement policies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Market, by Biomarker

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Extracellular Vesicles

7. Breast Cancer Liquid Biopsy Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Physician Laboratories
  • 7.3. Reference Laboratories

8. Americas Breast Cancer Liquid Biopsy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptive Biotechnologies Corporation
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Biocept, Inc.
  • 4. Biodesix, Inc.
  • 5. Epic Sciences Inc.
  • 6. Exact Sciences Corporation
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Fluxion Biosciences Inc.
  • 9. Guardant Health, Inc.
  • 10. Illumina, Inc.
  • 11. Johnson & Johnson Services, Inc.
  • 12. NeoGenomics Laboratories, Inc.
  • 13. Qiagen N. V. by Thermo Fisher Scientific Inc.
  • 14. Sysmex Corporation
  • 15. The Menarini Group

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023